LONDON: Aptamer Group plc (AIM: APTA), the developer of novel Optimer binders to enable innovation in the life sciences industry, is pleased to announce that it has extended its collaboration agreement with PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, to develop four new Optimer-drug conjugates for use as precision chemotherapeutics. The partnership commenced in…